Dr. Marta Peciña, MD, PhD
Claim this profileMore about Marta Peciña, MD, PhD
Clinical Trial Related
5 years of experience running clinical trials · Led 1 trial as a Principal Investigator · 0 Active Clinical Trials
Treatments Marta Peciña, MD, PhD has experience with
- Buprenorphine
- Naltrexone
- Theta Burst Stimulation
Breakdown of trials Marta Peciña, MD, PhD has run
Major Depressive Disorder
Depression
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Marta Peciña, MD, PhD specialize in?
Marta Peciña, MD, PhD focuses on Major Depressive Disorder and Depression. In particular, much of their work with Major Depressive Disorder has involved treating patients, or patients who are undergoing treatment.
Is Marta Peciña, MD, PhD currently recruiting for clinical trials?
No, Marta Peciña, MD, PhD is not currently recruiting for any clinical trials. This may change in the future, so check back later.
Are there any treatments that Marta Peciña, MD, PhD has studied deeply?
Yes, Marta Peciña, MD, PhD has studied treatments such as Buprenorphine, Naltrexone, Theta Burst Stimulation.
What is the best way to schedule an appointment with Marta Peciña, MD, PhD?
Apply for one of the trials that Marta Peciña, MD, PhD is conducting.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.